Secretome proteomics for discovery of cancer biomarkers

Journal of Proteomics

Volumn 73, Issue 12, 2010, Pages 2291-2305

  Makridakis, Manousos ^a   Vlahou, Antonia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Biomarkers; Cancer; Proteomics; Secretome

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CA 15-3 ANTIGEN; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; CLUSTERIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; DESMOPLAKIN; DISINTEGRIN; ELAFIN; GALECTIN 1; GELATINASE A; GROWTH DIFFERENTIATION FACTOR 15; INTESTINAL TREFOIL FACTOR; KALLIKREIN 6; LEPTIN; LIPOCORTIN 4; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEONECTIN; PEROXIREDOXIN 2; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN DISULFIDE ISOMERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINOIC ACID BINDING PROTEIN; SCLEROPROTEIN; TETRATRICOPEPTIDE REPEAT PROTEIN; TUMOR MARKER; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNINDEXED DRUG;

AMNION FLUID; ASCITES FLUID; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL LYSATE; CELL STRAIN MCF 7; CEREBROSPINAL FLUID; COLORECTAL CANCER; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTERSTITIAL FLUID; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LUNG CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MILK; MOUTH CARCINOMA; NASOPHARYNX CANCER; NEOPLASM; OVARY CANCER; OVARY FOLLICLE FLUID; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REVIEW; SALIVA; SECRETOME; SEMINAL PLASMA; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; URINE; WESTERN BLOTTING;

BODY FLUIDS; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HODGKIN DISEASE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MOUTH NEOPLASMS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASMS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77957755656     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.07.001     Document Type: Review

References (108)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Kulasingam V., Diamandis E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008, 5:588-599.
3. Xue H., Lu B., Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med 2008, 6:52.
4. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3:243-252.
5. Pavlou M.P., Diamandis E.P. The cancer cell secretome: a good source for discovering biomarkers?. J Proteomics Apr 12 2010.
6. May M. From cells, secrets of the secretome leak out. Nat Med 2009, 15:828.
7. Tjalsma H., Bolhuis A., Jongbloed J.D., Bron S., van Dijl J.M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 2000, 64:515-547.
8. Bouws H., Wattenberg A., Zorn H. Fungal secretomes-nature's toolbox for white biotechnology. Appl Microbiol Biotechnol 2008, 80:381-388.
9. Katz-Jaffe M.G., McReynolds S., Gardner D.K., Schoolcraft W.B. The role of proteomics in defining the human embryonic secretome. Mol Hum Reprod 2009, 15:271-277.
10. Chevallet M., Diemer H., Van Dorssealer A., Villiers C., Rabilloud T. Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics 2007, 7:1757-1770.
11. Mbeunkui F., Fodstad O., Pannell L.K. Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. J Proteome Res 2006, 5:899-906.
12. Cooper S. Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. FASEB J 2003, 17:333-340.
13. Shin J.S., Hong S.W., Lee S.L., Kim T.H., Park I.C., An S.K., et al. Serum starvation induces G1 arrest through suppression of Skp2-CDK2 and CDK4 in SK-OV-3 cells. Int J Oncol 2008, 32:435-439.
14. Hasan N.M., Adams G.E., Joiner M.C. Effect of serum starvation on expression and phosphorylation of PKC-alpha and p53 in V79 cells: implications for cell death. Int J Cancer 1999, 80:400-405.
15. Levin V.A., Panchabhai S.C., Shen L., Kornblau S.M., Qiu Y., Baggerly K.A. Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res 2010, 9:179-191.
16. Lawlor K., Nazarian A., Lacomis L., Tempst P., Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res 2009, 8:1489-1503.
17. Kulasingam V., Diamandis E.P. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 2007, 6:1997-2011.
18. Gunawardana C.G., Kuk C., Smith C.R., Batruch I., Soosaipillai A., Diamandis E.P. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res 2009, 8:4705-4713.
19. Sardana G., Jung K., Stephan C., Diamandis E.P. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008, 7:3329-3338.
20. Zwickl H., Traxler E., Staettner S., Parzefall W., Grasl-Kraupp B., Karner J., et al. A novel technique to specifically analyze the secretome of cells and tissues. Electrophoresis 2005, 26:2779-2785.
21. Colzani M., Waridel P., Laurent J., Faes E., Ruegg C., Quadroni M. Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. J Proteome Res 2009, 8:4779-4788.
22. Chen S.T., Pan T.L., Juan H.F., Chen T.Y., Lin Y.S., Huang C.M. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res 2008, 7:1379-1387.
23. Huang C.M., Ananthaswamy H.N., Barnes S., Ma Y., Kawai M., Elmets C.A. Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics 2006, 6:6107-6116.
24. Huang C.M., Wang C.C., Barnes S., Elmets C.A. In vivo detection of secreted proteins from wounded skin using capillary ultrafiltration probes and mass spectrometric proteomics. Proteomics 2006, 6:5805-5814.
25. Huang C.M., Wang C.C., Kawai M., Barnes S., Elmets C.A. In vivo protein sampling using capillary ultrafiltration semi-permeable hollow fiber and protein identification via mass spectrometry-based proteomics. J Chromatogr A 2006, 1109:144-151.
26. Huang C.M., Wang C.C., Kawai M., Barnes S., Elmets C.A. Surfactant sodium lauryl sulfate enhances skin vaccination: molecular characterization via a novel technique using ultrafiltration capillaries and mass spectrometric proteomics. Mol Cell Proteomics 2006, 5:523-532.
27. Maresh G.A., Dunbar B.S. A simple, inexpensive method for the salt-free concentration of proteins for analysis by two-dimensional gel electrophoresis. Electrophoresis 1988, 9:54-57.
28. Ziegler J., Vogt T., Miersch O., Strack D. Concentration of dilute protein solutions prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1997, 250:257-260.
29. Sauve D.M., Ho D.T., Roberge M. Concentration of dilute protein for gel electrophoresis. Anal Biochem 1995, 226:382-383.
30. Bensadoun A., Weinstein D. Assay of proteins in the presence of interfering materials. Anal Biochem 1976, 70:241-250.
31. Makridakis M., Roubelakis M.G., Bitsika V., Dimuccio V., Samiotaki M., Kossida S., et al. Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J Proteome Res May 13 2010.
32. Righetti P.G., Boschetti E., Lomas L., Citterio A. Protein Equalizer Technology: the quest for a "democratic proteome". Proteomics 2006, 6:3980-3992.
33. Thulasiraman V., Lin S., Gheorghiu L., Lathrop J., Lomas L., Hammond D., et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005, 26:3561-3571.
34. Archakov A.I., Ivanov Y.D., Lisitsa A.V., Zgoda V.G. AFM fishing nanotechnology is the way to reverse the Avogadro number in proteomics. Proteomics 2007, 7:4-9.
35. Cao J., Hu Y., Shen C., Yao J., Wei L., Yang F., et al. Nanozeolite-driven approach for enrichment of secretory proteins in human hepatocellular carcinoma cells. Proteomics 2009, 9:4881-4888.
36. Wu H.Y., Chang Y.H., Chang Y.C., Liao P.C. Proteomics analysis of nasopharyngeal carcinoma cell secretome using a hollow fiber culture system and mass spectrometry. J Proteome Res 2009, 8:380-389.
37. Piersma S.R., Fiedler U., Span S., Lingnau A., Pham T.V., Hoffmann S., et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 2010, 9:1913-1922.
38. Planque C., Kulasingam V., Smith C.R., Reckamp K., Goodglick L., Diamandis E.P. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009, 8:2746-2758.
39. Kulasingam V., Diamandis E.P. Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008, 123:2007-2012.
40. Dinney C.P., McConkey D.J., Millikan R.E., Wu X., Bar-Eli M., Adam L., et al. Focus on bladder cancer. Cancer Cell 2004, 6:111-116.
41. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
42. Tada Y., Wada M., Taguchi K., Mochida Y., Kinugawa N., Tsuneyoshi M., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002, 62:4048-4053.
43. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61:1265-1268.
44. Kawanishi H., Matsui Y., Ito M., Watanabe J., Takahashi T., Nishizawa K., et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008, 14:2579-2587.
45. Lin C.Y., Tsui K.H., Yu C.C., Yeh C.W., Chang P.L., Yung B.Y. Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 2006, 6:4381-4389.
46. Makridakis M., Gagos S., Petrolekas A., Roubelakis M.G., Bitsika V., Stravodimos K., et al. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics 2009, 9:287-298.
47. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212.
48. Kulasingam V., Zheng Y., Soosaipillai A., Leon A.E., Gion M., Diamandis E.P. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 2009, 125:9-14.
49. Gromov P., Gromova I., Bunkenborg J., Cabezon T., Moreira J.M., Timmermans-Wielenga V., et al. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 2010, 4:65-89.
50. Liang X., Huuskonen J., Hajivandi M., Manzanedo R., Predki P., Amshey J.R., et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009, 9:182-193.
51. Mbeunkui F., Metge B.J., Shevde L.A., Pannell L.K. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 2007, 6:2993-3002.
52. Lai T.C., Chou H.C., Chen Y.W., Lee T.R., Chan H.T., Shen H.H., et al. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res 2010, 9:1302-1322.
53. Perera C.N., Spalding H.S., Mohammed S.I., Camarillo I.G. Identification of proteins secreted from leptin stimulated MCF-7 breast cancer cells: a dual proteomic approach. Exp Biol Med (Maywood) 2008, 233:708-720.
54. Guthrie J.A. Colorectal cancer: follow-up and detection of recurrence. Abdom Imaging 2002, 27:570-577.
55. Jonas S., Thelen A., Benckert C., Spinelli A., Sammain S., Neumann U., et al. Extended resections of liver metastases from colorectal cancer. World J Surg 2007, 31:511-521.
56. Smith J.J., Deane N.G., Dhawan P., Beauchamp R.D. Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery 2008, 144:353-366.
57. Xue H., Lu B., Zhang J., Wu M., Huang Q., Wu Q., et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010, 9:545-555.
58. Wu C.C., Chen H.C., Chen S.J., Liu H.P., Hsieh Y.Y., Yu C.J., et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8:316-332.
59. Wu C.C., Huang Y.S., Lee L.Y., Liang Y., Tang R.P., Chang Y.S., et al. Overexpression and elevated plasma level of tumor-associated antigen 90K/Mac-2 binding protein in colorectal carcinoma. Proteomics Clin Appl 2008, 2:1586-1595.
60. Klein-Scory S., Kubler S., Diehl H., Eilert-Micus C., Reinacher-Schick A., Stuhler K., et al. Immunoscreening of the extracellular proteome of colorectal cancer cells. BMC Cancer 2010, 10:70.
61. Volmer M.W., Stuhler K., Zapatka M., Schoneck A., Klein-Scory S., Schmiegel W., et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5:2587-2601.
62. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
63. Miyaki M., Iijima T., Konishi M., Sakai K., Ishii A., Yasuno M., et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999, 18:3098-3103.
64. Shi H.J., Stubbs R., Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis 2009, 30:2442-2453.
65. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
66. Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., et al. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol 2010, 2010:437143.
67. Yamashita R., Fujiwara Y., Ikari K., Hamada K., Otomo A., Yasuda K., et al. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem 2007, 298:83-92.
68. Slany A., Haudek V.J., Zwickl H., Gundacker N.C., Grusch M., Weiss T.S., et al. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res 2010, 9:6-21.
69. Crane L.J., Miller D.L. Plasma protein synthesis by isolated rat hepatocytes. J Cell Biol 1977, 72:11-25.
70. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99:4283-4297.
71. Ma Y., Visser L., Roelofsen H., de Vries M., Diepstra A., van Imhoff G., et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008, 111:2339-2346.
72. Chen G., Gharib T.G., Wang H., Huang C.C., Kuick R., Thomas D.G., et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003, 100:13537-13542.
73. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
74. Xiao T., Ying W., Li L., Hu Z., Ma Y., Jiao L., et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005, 4:1480-1486.
75. Wang C.L., Wang C.I., Liao P.C., Chen C.D., Liang Y., Chuang W.Y., et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res 2009, 8:4428-4440.
76. Lou X., Xiao T., Zhao K., Wang H., Zheng H., Lin D., et al. Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 2007, 6:1083-1092.
77. Lu Y.J., Guo S.P., Tong T., Xu L.H., Dong X.Y., Hana N.J., et al. Establishment and characterization of a SV40T-transformed human bronchial epithelial cell line. Lung Cancer 1998, 19:15-24.
78. Chen Y., Zhang H., Xu A., Li N., Liu J., Liu C., et al. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 2006, 54:95-102.
79. Kim J.E., Koo K.H., Kim Y.H., Sohn J., Park Y.G. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med 2008, 40:709-720.
80. Chenau J., Michelland S., de Fraipont F., Josserand V., Coll J.L., Favrot M.C., et al. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 2009, 8:4579-4591.
81. Miller A.J., Mihm M.C. Melanoma. N Engl J Med 2006, 355:51-65.
82. Paulitschke V., Kunstfeld R., Mohr T., Slany A., Micksche M., Drach J., et al. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 2009, 8:2501-2510.
83. Chan K.C., Lo Y.M. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:489-496.
84. Wu C.C., Chien K.Y., Tsang N.M., Chang K.P., Hao S.P., Tsao C.H., et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5:3173-3182.
85. Chang Y.H., Wu C.C., Chang K.P., Yu J.S., Chang Y.C., Liao P.C. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J Proteome Res 2009, 8:5465-5474.
86. Funk G.F., Karnell L.H., Robinson R.A., Zhen W.K., Trask D.K., Hoffman H.T. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002, 24:165-180.
87. Muir C., Weiland L. Upper aerodigestive tract cancers. Cancer 1995, 75:147-153.
88. Reid B.C., Winn D.M., Morse D.E., Pendrys D.G. Head and neck in situ carcinoma: incidence, trends, and survival. Oral Oncol 2000, 36:414-420.
89. Weng L.P., Wu C.C., Hsu B.L., Chi L.M., Liang Y., Tseng C.P., et al. Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J Proteome Res 2008, 7:3765-3775.
90. Mlynarek A.M., Balys R.L., Su J., Hier M.P., Black M.J., Alaoui-Jamali M.A. A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007, 133:910-918.
91. Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R., Pitteri S.J., Green A.E., et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE 2008, 3:e2425.
92. Berchuck A., Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997, 54:541-544.
93. Bookman M.A. Biological therapy of ovarian cancer: current directions. Semin Oncol 1998, 25:381-396.
94. Gortzak-Uzan L., Ignatchenko A., Evangelou A.I., Agochiya M., Brown K.A., St Onge P., et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008, 7:339-351.
95. Westermann A.M., Beijnen J.H., Moolenaar W.H., Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat Rev 1997, 23:113-131.
96. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006, 20:197-209.
97. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
98. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006, 5:157-171.
99. Ryan C.J., Small E.J. Progress in detection and treatment of prostate cancer. Curr Opin Oncol 2005, 17:257-260.
100. Sardana G., Marshall J., Diamandis E.P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007, 53:429-437.
101. Martin D.B., Gifford D.R., Wright M.E., Keller A., Yi E., Goodlett D.R., et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004, 64:347-355.
102. Sarkissian G., Fergelot P., Lamy P.J., Patard J.J., Culine S., Jouin P., et al. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 2008, 54:574-581.
103. Bonin-Debs A.L., Boche I., Gille H., Brinkmann U. Development of secreted proteins as biotherapeutic agents. Expert Opin Biol Ther 2004, 4:551-558.
104. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., Chang K.P., Tai D.I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
105. Narimatsu H., Sawaki H., Kuno A., Kaji H., Ito H., Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010, 277:95-105.
106. Wei X., Li L. Comparative glycoproteomics: approaches and applications. Brief Funct Genomic Proteomic 2009, 8:104-113.
107. Pan S., Zhang H., Rush J., Eng J., Zhang N., Patterson D., et al. High throughput proteome screening for biomarker detection. Mol Cell Proteomics 2005, 4:182-190.
108. Stahl-Zeng J., Lange V., Ossola R., Eckhardt K., Krek W., Aebersold R., et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007, 6:1809-1817.